|Bid||10.00 x 800|
|Ask||13.00 x 1100|
|Day's Range||10.45 - 11.06|
|52 Week Range||6.03 - 14.20|
|Beta (5Y Monthly)||2.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.40|
Pharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in. Many individuals are born with disorders for which there is no cure,
CAMBRIDGE, Mass., Jun 14, 2021--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer.
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021.